Body mass index predicts the incidence of radiation pneumonitis in breast cancer patients.

Publication/Presentation Date

1-1-2005

Abstract

In patients receiving breast radiotherapy, the risk of radiation pneumonitis has been associated with the volume of irradiated lung, and concomitant methotrexate, paclitaxel, and tamoxifen therapy. Many of the studies of radiation pneumonitis are based on estimates of pulmonary risk using central lung distance that is calculated using two-dimensional techniques. With the treatment of internal mammary nodes and three-dimensional treatment planning for breast cancer becoming increasingly more common, there is a need to further consider the impact of dose-volume metrics in assessing radiation pneumonitis risk. We herein present a case control study assessing the impact of clinical and dose-volume metrics on the development of radiation pneumonitis in patients receiving sequential chemotherapy and local-regional radiotherapy.

Volume

11

Issue

5

First Page

390

Last Page

398

ISSN

1528-9117

Disciplines

Medicine and Health Sciences | Oncology

PubMedID

16267908

Department(s)

Department of Radiation Oncology

Document Type

Article

Share

COinS